Journal of Medicinal Chemistry p. 1084 - 1104 (2020)
Update date:2022-08-15
Topics:
Kurasawa, Osamu
Miyazaki, Tohru
Homma, Misaki
Oguro, Yuya
Imada, Takashi
Uchiyama, Noriko
Iwai, Kenichi
Yamamoto, Yukiko
Ohori, Momoko
Hara, Hideto
Sugimoto, Hiroshi
Iwata, Kentaro
Skene, Robert
Hoffman, Isaac
Ohashi, Akihiro
Nomura, Toshiyuki
Cho, Nobuo
In our pursuit of developing a novel, potent, and selective cell division cycle 7 (Cdc7) inhibitor, we optimized the previously reported thieno[3,2-d]pyrimidinone analogue I showing time-dependent Cdc7 kinase inhibition and slow dissociation kinetics. These medicinal chemistry efforts led to the identification of compound 3d, which exhibited potent cellular activity, excellent kinase selectivity, and antitumor efficacy in a COLO205 xenograft mouse model. However, the issue of formaldehyde adduct formation emerged during a detailed study of 3d, which was deemed an obstacle to further development. A structure-based approach to circumvent the adduct formation culminated in the discovery of compound 11b (TAK-931) possessing a quinuclidine moiety as a preclinical candidate. In this paper, the design, synthesis, and biological evaluation of this series of compounds will be presented.
View MoreNingBO Hong Xiang Biochem.Co.Ltd
website:http://www.hxbiochem.com
Contact:0574-66003444
Address:Ning Bo Bei Lun
website:http://www.tbbmed.com
Contact:86--21-50498136
Address:Room 6002, Building 7-1, No.160 Basheng Road,Pudong Area,Shanghai China
Contact:+86-22-26358246
Address:601-4-20, Fujiayuan, Tiantai Road, Hebei District, Tianjin, China
Contact:0513-68015397
Address:NO.100 lake dongting road linjiang town haimen
Contact:0086-29-88315623
Address:S711, Innovation Bldg No.25 Gaoxin 1st Rd, Xian P.R of China 710075
Doi:10.1246/bcsj.62.3691
(1989)Doi:10.1007/BF00912610
(1974)Doi:10.1016/S0040-4020(01)91019-1
(1991)Doi:10.1021/acs.orglett.7b04042
(2018)Doi:10.1021/jacs.9b11601
(2019)Doi:10.1002/jlac.197419740208
(1974)